The effect of mirtazapine on neuroleptic-induced acute akathisia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191218045795N5

Enrollment

Registered

2022-03-17

Start date

2022-02-07

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

????????. Drug induced akathisia

Interventions

Intervention 1: Intervention group: The intervention in this study is mirtazapine. First, mirtazapine powder (manufactured by Tekaje-Iran under the brand name Rpizapine) which is prepared by a pharmac

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: currently onantipsychotic medication; a score of at least 2(mild akathisia) on the global subscale of theBarnes Akathisia Rating Scale (BARS)

Exclusion criteria

Exclusion criteria: aking betablocker, cyproheptadin ,miancerin, Vitamin B6 suiccidal thoughtsevere akathisia ,global score of BARS >5

Design outcomes

Primary

Measure	Time frame
BARS akathisia score. Timepoint: before intervention and 5 day after intervention. Method of measurement: BARS akathisia questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Shamsalizadeh

Sanandaj University of Medical Sciences

nshamsalizadeh@yahoo.com+98 87 3366 4957

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026